Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fabrazyme ERT in Chinese Participants with Fabry Disease
NCT05054387Phase 4Completed
- Sponsor
- Sanofi
- Start
- Oct 2021
- Primary completion
- Mar 2023
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of agalsidase beta in Fabry disease (FD), sponsored by Sanofi. Primary endpoint: Incidence of treatment-emergent adverse events at Week 50. Started Oct 2021; status: completed.
02
Drugs
agalsidase beta
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT05054387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05054387.